Efficacy and safety of Hyadex for treatment of vesicoureteral reflux: a multicenter experience

Basit Öğe Kaydı
dc.authoridyağmur, ismail/0000-0002-4208-5095
dc.authoridGüngör, Hasan/0000-0003-4059-0597
dc.authorwosidyağmur, ismail/ABF-7274-2020
dc.authorwosidGüngör, Hasan/AEV-5818-2022
dc.contributor.authorOguz, Fatih
dc.contributor.authorYildiz, Turan
dc.contributor.authorGecit, Ilhan
dc.contributor.authorGungor, Hasan
dc.contributor.authorCiftci, Halil
dc.contributor.authorAksoy, Yilmaz
dc.contributor.authorYagmur, Ismail
dc.date.accessioned2024-08-04T20:54:38Z
dc.date.available2024-08-04T20:54:38Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectiveThis study was performed to evaluate the efficacy and safety of dextranomer/cross-linked hyaluronic acid (Hyadex) in patients with a clinical diagnosis of vesicoureteral reflux (VUR).MethodsIn this cross-sectional multicenter observational study, Hyadex was used in four different centers for the endoscopic treatment of VUR from 2020 to 2022. The study involved 74 patients (93 renal units) who were diagnosed with VUR according to voiding cystourethrography (VCUG) findings and were considered suitable for subureteric endoscopic treatment. The follow-up time (control VCUG time) was 3 months.ResultsIn the VCUG evaluation, grade I VUR was found in 13 renal units, grade II in 23 renal units, grade III in 42 renal units, and grade IV in 12 renal units. The success rates of Hyadex treatment according to the degree of VUR were as follows: 84.6% for grade I, 82.6% for grade II, 71.4% for grade III, and 66.0% for grade IV. No major complications were observed.ConclusionEndoscopic subureteric Hyadex injection had high success rates in appropriately selected patients with VUR and may be used as the first-line treatment for children with VUR.en_US
dc.identifier.doi10.1177/03000605231195165
dc.identifier.issn0300-0605
dc.identifier.issn1473-2300
dc.identifier.issue8en_US
dc.identifier.pmid37646623en_US
dc.identifier.scopus2-s2.0-85168927059en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1177/03000605231195165
dc.identifier.urihttps://hdl.handle.net/11616/101543
dc.identifier.volume51en_US
dc.identifier.wosWOS:001057771700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of International Medical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVesicoureteral refluxen_US
dc.subjectsubureteric injectionen_US
dc.subjectdextranomeren_US
dc.subjectcross-linked hyaluronic aciden_US
dc.subjectHyadexen_US
dc.subjectvoiding cystourethrographyen_US
dc.titleEfficacy and safety of Hyadex for treatment of vesicoureteral reflux: a multicenter experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu